HDAC Inhibitors (Histone Deacetylase Inhibitors)

Description

HDAC inhibitors (HDACi) are compounds that block histone deacetylases — enzymes that remove acetyl groups from histone lysine residues. Inhibiting HDACs leads to histone hyperacetylation, which opens chromatin and generally promotes gene expression.

Relevance to Psychiatry

Antidepressant Effects

HDAC inhibitors produce antidepressant-like effects in rodent stress models. This was among the first observations implicating epigenetic mechanisms in depression.

Evidence (animal models):

Systemic sodium butyrate (nonspecific HDACi): antidepressant-like effects in chronic social defeat stress model
Intra-NAc injection of MS275 (more selective HDACi): alleviates defeat-induced depression-like symptoms
Intra-hippocampal and intra-PFC injection of HDACi: antidepressant effects
Genome-wide expression analysis: HDACi treatment (MS275) and fluoxetine both reverse a large proportion of defeat-induced gene expression changes; significant overlap between the two treatments

Proposed mechanism: Defeat stress causes hypoacetylation of histones at genes involved in stress susceptibility. HDAC inhibition restores acetylation → restores expression of suppressed genes → antidepressant behavioral response.

Human evidence: Limited. Elevated H3K4me3 (activation mark) found at synapsin genes in depressed human PFC. No clinical trials of HDACi as antidepressants established.

Schizophrenia

HDAC2 has been implicated in antipsychotic drug action in rodent models
HDACi can modify expression of GABAergic promoters; antipsychotics differ in this ability
Clinical application: investigational only

Early Life Stress / Developmental Models

HDAC inhibitors (trichostatin A) reverse the effects of low maternal care on Nr3c1 histone acetylation and stress behavior in rodents
Treatment with theophylline (HDAC activator) has the opposite effect

Evidence Quality

Application	Evidence Level	Notes
Antidepressant (animal models)	Strong	Multiple paradigms, multiple brain regions
Antidepressant (human)	Weak	Mechanistic inference only; no established clinical trials
Reversing early-life stress effects (animals)	Moderate	Replicated at specific loci
Antipsychotic augmentation	Weak	Preliminary rodent data only

Limitations and Concerns

Current HDACi (e.g., sodium butyrate, MS275, trichostatin A) are highly nonspecific — affect hundreds or thousands of genes genome-wide
HDAC family has multiple isoforms (HDAC1–11, sirtuins); isoform-specific functions in psychiatric contexts largely unknown
Systemic HDACi would affect all tissues, raising toxicity concerns for psychiatric use
Locus-specific approaches (zinc finger proteins, CRISPR-based epigenome editing targeting individual genes) are being developed to overcome this limitation

Side Effects

Broad epigenetic effects across the genome
In oncology (where HDACi are approved), side effects include fatigue, nausea, thrombocytopenia, and cardiac arrhythmias
Safety profile for chronic psychiatric use is unstudied